Tracking Progress with in-Office MGD Treatment

Use four measures of progress

Track symptoms and daily function

Record how your eyes feel and what they let you do. Useful entries include burning, grittiness, fluctuating blur, light sensitivity, contact lens tolerance, screen time, reading, driving, and how often you reach for lubricating drops. Dry eye can cause scratchiness, stinging or burning, redness, light sensitivity, and blurry vision. ¹ The most meaningful change is one you can describe in ordinary life, such as finishing a work shift with fewer breaks.

Track gland and tear-film findings

Clinicians can assess meibum quality, quantity, and expressibility, the number and location of expressible glands, tear break-up time, and ocular-surface staining. ² These measurements answer different questions. Symptoms and objective signs may not change together, and pooled thermal-pulsation results have differed across gland, staining, tear-stability, lipid-layer, and symptom outcomes. ² ³

A mixed result does not settle the whole question. The relationship between dry-eye symptoms and signs is not linear and varies among people and dry-eye types. ² If one measure improves and another does not, compare both with the baseline goal and ask what the difference changes in the plan.

Track tolerance and the treatment plan

Write down the exact procedure, treatment date, eye or eyelids treated, other therapies continued, and any reaction afterward. Keep each entry short and use the same format. A complete record makes it easier to decide whether to continue, adjust, repeat, or investigate another cause. For a related symptom pattern, read Menopause-Related Dry Eye Changes to Monitor.

A simple tracker can fit on one page. Use columns for date, procedure or session number, symptom score, one daily task, drop use, unexpected effects, and questions. Add the clinic’s baseline values at the top. Bring the same page to every visit so the conversation begins with a trend rather than a memory of only the best or worst day. You can compare this topic with Monitoring Demodex Blepharitis during Treatment.

Choose the smallest record you can maintain consistently. A thirty-second entry completed most days is more useful than an elaborate form abandoned after a week. Keep the raw entries and add a short weekly summary: better, unchanged, worse, or mixed, followed by one concrete example. That summary gives the visit a clear starting point while preserving the details if the clinician needs them. For another care decision in this area, see Menopause-Related Dry Eye Symptoms to Recognize.

What “in-office MGD treatment” can mean

Heat and expression procedures

Physical treatments for obstructive meibomian gland dysfunction may use heat to soften obstructive material, pressure to express gland contents, or both; examples include manual expression and device-assisted thermal pulsation. ⁴ Record the device or technique rather than writing only “dry-eye treatment,” because expected schedules and comparisons differ.

Light, probing, and lid-margin procedures

Other in-office approaches described in the reviewed sources include intense pulsed light (IPL) and intraductal probing. ⁵ ⁴ Ask the clinic to match the monitoring dates and safety questions to the procedure and protocol used.

Confirm what is being treated

MGD should be part of the working diagnosis

Assessing meibomian gland dysfunction, tear lipid thickness and dynamics, and tear volume helps clinicians subclassify dry-eye disease. ² Ask which examination findings support MGD and whether another dry-eye driver is also present. Dry-eye treatment depends on the cause, and treating another contributing condition may improve symptoms. ¹

One image or symptom score is not enough

Meibography alone does not appear to be sufficient for diagnosing MGD and should be interpreted with other clinical findings. ² A treatment decision should connect your symptoms and function with the examination, rather than treating one photograph or number in isolation.

Build the baseline before treatment

Choose one repeatable symptom measure

TFOS recommends the DEQ-5 or OSDI for dry-eye symptom screening. ² Use the same questionnaire version at baseline and follow-up. Add one personal function goal, such as reading for 45 minutes or wearing contact lenses for a defined period, so the result has practical meaning.

Record the examination measures that will be repeated

Ask the clinician which findings will define a response. Common research and clinical outcomes include tear break-up time, meibomian gland expression or yielding-secretion scores, corneal fluorescein staining, lipid-layer thickness, osmolarity, and lid-margin findings. ³ ⁵ You do not need every test. You need the same relevant measures repeated in a comparable way.

Make a small comparison card with four rows: symptoms, daily function, gland findings, and ocular-surface findings. In each row, list the baseline, the follow-up result, and what the difference means. Leave a blank when a measure was not repeated. This prevents a missing number from being mistaken for either improvement or failure.

Agree on the comparison date

Before treatment, write down when the planned course ends and when the clinician wants to judge response. Short follow-up in the thermal-pulsation trials makes long-term effectiveness and safety difficult to evaluate. ³ A next-day impression and a scheduled follow-up answer different questions.

How treatment goals connect to measurements

Expression measures whether oil can leave the glands

Meibum quantity, quality, and expressibility reflect gland function; clinicians can score the number and location of expressible glands and their response to different levels of pressure. ² A useful follow-up note states whether more glands produce secretion and whether the secretion quality changed, using the same scale when possible.

Tear stability and staining assess the ocular surface

TFOS dry-eye diagnostic testing includes tear break-up time, osmolarity, and ocular-surface staining with fluorescein and lissamine green. ² These findings should be interpreted alongside symptoms because the relationship between dry-eye symptoms and signs is not linear and varies among people. ²

Meibography documents structure

Several scoring scales are used to evaluate meibography, but meibography alone is not sufficient to diagnose MGD and should be interpreted with other clinical parameters. ² Ask the clinician what change the image is realistically expected to show over the chosen interval and whether repeating it would alter the plan.

Check safety before each treatment

Review procedure-specific exclusions

The safety checklist depends on the exact device and technique. Bring an updated list of eye conditions, recent eye procedures, skin conditions around the treatment area, medicines, allergies, and any reaction to a previous session. Ask the clinician to explain why the selected procedure is appropriate for you and which instructions apply before the next session.

Pause when the eye has changed

Contact the treating office before a scheduled session if you develop a new painful red eye, light sensitivity, a meaningful vision change, or an eye injury. ⁶ The clinician can decide whether to examine you first or change the plan. Do not use a prepaid series or calendar date as automatic clearance.

Track progress from treatment day to follow-up

On treatment day

Record symptoms before the procedure, then note the procedure name and immediate comfort afterward. Avoid declaring success or failure from the first few hours. Your baseline is the comparison point, and the agreed follow-up date is the main assessment.

During the first several days

Use one daily entry at roughly the same time. Rate no more than three symptoms, record drop use, and note one function that mattered that day. Also document unexpected redness, pain, skin change, lash change, or sustained blur. Dry-eye signs and symptoms can fluctuate over time, so one unusually good or bad day should be interpreted within the broader pattern. ²

Keep the scale stable. If zero means no discomfort on the first day, it should mean the same thing later. Add a short note when conditions were unusual, such as long travel, smoke exposure, a new medicine, or much more screen use. The note helps explain the number without changing the scale.

Across a multi-session course

Keep the same measures after every session. Record other treatment changes, including new drops, warm-compress routines, contact lens changes, or environmental changes. If several things change at once, the overall plan may still help, but it becomes harder to attribute improvement to one procedure.

At the scheduled reassessment

Bring your brief log and ask for a side-by-side comparison with baseline. Review symptoms, your personal function goal, gland expression, tear stability, staining, and any selected imaging. End with one written decision: continue the course, maintain the current plan, modify treatment, investigate another contributor, or observe until another defined date.

Ask the clinician to summarize the decision in one sentence and name the next checkpoint. For example: continue home care and reassess function in six weeks, or pause further procedures while another contributor is evaluated. A dated decision keeps “wait and see” from becoming an open-ended plan.

Before leaving, photograph or copy the comparison values and the plan. Label each number with the test name, eye, date, and unit. A bare number in a patient portal may be impossible to interpret later. Keep the original wording of the clinician’s conclusion, then add your own reminder about the next action and appointment.

Interpret mixed or incomplete results

Symptoms and signs may move differently

A 2025 systematic review of 18 randomized thermal-pulsation trials found improvement in some gland-function and ocular-surface outcomes, while the pooled OSDI symptom result was not significantly better than controls and study results varied. ³ This is a reason to review several measures, not a reason to dismiss either your symptoms or the examination.

Evidence differs by procedure

The Cochrane review of IPL for MGD found low- or very-low-certainty evidence and could not determine effectiveness or safety with certainty from the available trials. ⁵ The TFOS management report also noted that many dry-eye treatments lacked strong Level 1 evidence because of limitations such as masking, randomization, controls, selection bias, or sample size. ⁴ Ask what evidence applies to your specific procedure and diagnosis.

Do not promise a permanent result

The long-term benefit of thermal pulsation remains uncertain because many included studies had short follow-up, and TFOS identified the need for more research on maintenance regimens. ³ ⁴ Define the next monitoring point even if you improve. A useful plan states what maintenance means and what change would trigger reassessment.

When to contact the eye-care office

Seek prompt assessment for a significant new eye problem

Contact an eye-care professional promptly for severe or increasing eye pain, marked redness, new light sensitivity, or a meaningful change or loss of vision. ⁶ These findings should not be scored as routine “dryness” and watched until the next planned MGD visit. Tell the clinician what procedure you had and when.

Report treatment reactions and stalled function

IPL trials have reported mild eye pain, burning, and partial eyelash loss after device-use errors, while adverse-event reporting overall was limited. ⁵ Record a persistent or concerning treatment reaction and tell the treating office. Arrange a routine reassessment when the agreed goals have not changed by the planned review point. The National Eye Institute advises telling the eye doctor when dry eye interferes with everyday activities. ¹

Frequently asked questions about measuring progress

How soon should I expect improvement?

TFOS describes one LipiFlow study that reported outcomes at one month and a separate study of four in-office gland expressions over six months. ⁴ These examples do not set your personal timeline. Use the review date set for your exact procedure and ask what change is expected by then.

Which symptom score should I use?

TFOS recommends DEQ-5 or OSDI for dry-eye symptom screening, while the IPL trials in a Cochrane review used SPEED. ² ⁵ Use the measure your clinic can repeat and interpret. Consistency matters more than collecting several overlapping scores.

What if I feel better but the test numbers do not?

Bring the functional examples that improved and ask which test remained unchanged. Dry-eye symptoms and signs can be poorly correlated, so clinicians use multiple observations to interpret the pattern. ² The next step depends on which goal the treatment was meant to change.

What if tests improve but I do not feel better?

State this clearly. Ask whether the time interval is adequate, whether another dry-eye subtype or eyelid problem is present, and whether the treatment goal should change. The National Eye Institute says dry eye can occur when the eyes do not make enough tears or when the tears do not work correctly, and treatment usually depends on the cause. ¹

Should meibography be repeated after every session?

Meibography is useful for gland structure but should be interpreted with other clinical parameters. ² Ask whether a repeat image at that interval could change a decision. If it will not, symptom, function, secretion, stability, or staining measures may be more useful.

Does using fewer artificial tears prove the procedure worked?

Reduced drop use is a useful personal outcome, but record it alongside comfort and function. Environmental exposures and other medicines can cause or worsen dry-eye symptoms. ¹ Note these changes beside your lubricant count.